Alpha Cognition Inc. reported significant progress in 2024 so far, marked by key financial and corporate milestones. Alpha Cognition received approval for its flagship Alzheimer’s therapy ZUNVEYL (benzgalantamine), successfully raised ~$54.5M in financing, and completed the necessary preparations for listing on the NASDAQ exchange. These initiatives have positioned ACOG to launch ZUNVEYL in 1Q25, with an in place sales force, sufficient funding, and commercial production already underway.